Argos Therapeutics (ARGS) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARGS Hot Sheet
Join SI Premium – FREE
Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.83), $0.10 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $670 thousand.
For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Intel shares fall as competitor reports record results
- Citadel sees year-end stock rally as Wall Street’s biggest buyers return
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
